Matthew Harrison

Matthew Harrison Recent News

The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish
Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley.
Sarepta Falls To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new
Moderna Analyst: COVID-19 Vaccine Value Largely Reflected In Stock
A day ahead of an FDA panel meeting for Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, an analyst at Morgan Stanley stepped to the si
Biogen Analysts Brace For Favorable Aducanumab Adcom Verdict
Biogen Inc (NASDAQ: BIIB) shares saw a nice 40% bump Wednesday following the release of FDA briefing document prepared for Friday's Adcom meeting to discuss adu
COVID-19 Vaccines To Generate over $10B Annual Revenue, Analyst Say
A successful COVID-19 vaccine could be a bumper revenue opportunity for the pharmaceutical companies, with the market estimated to generate at least $10 billion in revenue a year, according to analysts.
2 Regeneron Analysts On COVID-19 Antibody Cocktail's Emergency Use Authorization Prospects
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.
2 Moderna Analysts On Chances Of COVID-19 Vaccine Approval, Upcoming Catalysts
Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program.
Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale
After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreemen
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts
Morgan Stanley Double Upgrades Biogen, Says Alzheimer's Opportunity Ahead
Although Biogen Inc (NASDAQ: BIIB) will face generic competitors for Tecfidera in the near term, the pricing in of aducanumab success may drive the stock to the mid-$300s, according to Morgan Stanley.
4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock
Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.
Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study
Moderna Inc (NASDAQ: MRNA) shares awere bulldozing their way toward  record highs Wednesday in reaction to the publication in the New England
Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success
Morgan Stanley, which recently named Moderna Inc (NASDAQ: MRNA) as one of the likeliest candidates to succeed in the coronavirus vaccine r
These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley
With about eight coronavirus vaccine candidates in clinical trials and 110 more in clinical testing, the race to a commercial product is intensifying. Against this backdrop, an analyst at Morgan Stanley looked at the most promising programs. 
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
Gilead Sciences, Inc.
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 thera
Analysts: Roche Partnership Derisks Sarepta Investor Concerns
8 Biotech Stocks Morgan Stanley Recommends For 2020
Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle'
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'